Compare Novavax Inc (NVAX) vs UiPath Inc (PATH) Price & Performance

Novavax (NVAX) trades at $10.19, down 0.29% today, with a bullish technical signal from moving averages but overbought RSI levels. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook. Key developments include regulatory approvals for its updated COVID-19 vaccine in the U.S., EU, and Japan for the 2026-2027 season, alongside ongoing partnerships with Sanofi and Pfizer.

The outlook is mixed: strong analyst buy ratings (73.9%) and partnership milestones offer upside, but negative net income margins and cash flow challenges pose risks. Investors should weigh the potential from vaccine demand and adjuvant platform royalties against financial sustainability concerns and competitive pressures in the biotech sector.

UiPath (PATH) is trading at $14.01, down 7.77% in the last 24 hours amid mixed technical signals and earnings volatility. The stock shows improving fundamentals with revenue growing from $892M in 2022 to $1.43B in 2025, though profitability remains negative with a -$73.69M net income. Recent Q2 2026 earnings beat expectations but guidance concerns triggered a selloff, with technical indicators showing bearish momentum despite oversold RSI conditions.

PATH presents a turnaround opportunity with strong revenue growth and improving margins, but faces execution risks in competitive AI automation. Analyst consensus targets $17.38 (24% upside) despite cautious ratings, with institutional interest growing. Key risks include sustained profitability challenges and AI competition, while positive cash flow trends and strategic positioning in enterprise automation offer long-term potential.